Breast Cancer Tucatinib Plus First-Line Maintenance Under Exploration in Metastatic HER2+ Breast CancerBy adminJune 8, 20220 Tucatinib plus first-line standard-of-care maintenance therapy with trastuzumab and pertuzumab is being investigated for its ability to improve progression-free survival…
